• Aliases: CC-4047, 3-amino-thalidomide
    • Derivative of thalidomide that acts as an antiangiogenic agent and immunomodulator
    • FDA approved in 2013 for the treatment of relapsed or refractory MM
    • Recommended dose: 4 mg PO daily on days 1 to 21 of the 28-day cycle
    • Half-life: 9.5 hours in healthy patients, 7.5 hours in patients with MM
    • Metabolism: Primarily metabolized by CYP1A2 and CYP3A, but is also a substrate of P-glycoprotein. Inhibitors of these enzymes should be avoided.
    • Common side effects: Fatigue, asthenia, neutropenia, anemia, constipation, diarrhea, nausea, back pain, dyspnea
    Other topics in Targeted and Immunotherapy Agents